Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders - A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline - Approved by the British Committee for Standards in Haematology

被引：121

作者：

Keeling, D. ^{[1
]}

Tait, C. ^{[2
]}

Makris, M. ^{[3
]}

机构：

[1] Churchill Hosp, Oxford Haemophilia & Thrombosis Ctr, Oxford, England

[2] Glasgow Royal Infirm, Haemophilia & Thrombosis Ctr, Glasgow G4 0SF, Lanark, Scotland

[3] Royal Hallamshire Hosp, Sheffield Haemopbilia & Thrombosis Ctr, Sheffield S10 2JF, S Yorkshire, England

来源：

HAEMOPHILIA | 2008年 / 14卷 / 04期

关键词：

haemophilia; inherited bleeding disorder; therapeutic; treatment;

D O I：

10.1111/j.1365-2516.2008.01695.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Evidence-based guidelines are presented on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. They include details of therapeutic products available in the UK and they update and replace previous United Kingdom Haemophilia Centre Doctors' Organisation guidelines.

引用

页码：671 / 684

页数：14

共 49 条

[1] Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VII inhibitor bypass activity [J].

Aledort, LM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1700-1708

[2] A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO [J].

Bolton-Maggs, Paula H. B. ;

Chalmers, Elizabeth A. ;

Collins, Peter W. ;

Harrison, Paul ;

Kitchen, Stephen ;

Liesner, Ri J. ;

Minford, Adrian ;

Mumford, Andrew D. ;

Parapia, Liakat A. ;

Perry, David J. ;

Watson, Steve P. ;

Wilde, Jonathan T. ;

Williams, Michael D. .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (05) :603-633

[3] The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation [J].

Bolton-Maggs, PHB ;

Perry, DJ ;

Chalmers, EA ;

Parapia, LA ;

Wilde, JT ;

Williams, MD ;

Collins, PW ;

Kitchen, S ;

Dolan, G ;

Mumford, AD .

HAEMOPHILIA, 2004, 10 (05) :593-628

[4] THROMBOGENIC POTENTIAL OF FACTOR-XI CONCENTRATE [J].

BOLTONMAGGS, PHB ;

COLVIN, BT ;

SATCHI, G ;

LEE, CA ;

LUCAS, GS .

LANCET, 1994, 344 (8924) :748-749

[5]

BOND L, 1988, NEW ENGL J MED, V318, P121

[6]

Carless PA, 2004, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD001884.PUB2

[7]

*CPMP, 2001, CPMPBWP26995REV3

[8]

DEBIASI R, 1991, BLOOD, V78, P1919

[9] INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].

EHRENFORTH, S ;

KREUZ, W ;

SCHARRER, I ;

LINDE, R ;

FUNK, M ;

GUNGOR, T ;

KRACKHARDT, B ;

KORNHUBER, B .

LANCET, 1992, 339 (8793) :594-598

[10] Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development [J].

Ettingshausen, C. Escuriola ;

Kreuz, W. .

HAEMOPHILIA, 2006, 12 :102-106

← 1 2 3 4 5 →